Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 210–218 | Cite as

Role of Interleukin-1 in Radiation-Induced Cardiomyopathy

  • Eleonora Mezzaroma
  • Ross B. Mikkelsen
  • Stefano Toldo
  • Adolfo G. Mauro
  • Khushboo Sharma
  • Carlo Marchetti
  • Asim Alam
  • Benjamin W. Van Tassell
  • David A. Gewirtz
  • Antonio Abbate
Research Article

Abstract

Thoracic X-ray therapy (XRT), used in cancer treatment, is associated with increased risk of heart failure. XRT-mediated injury to the heart induces an inflammatory response leading to cardiomyopathy. The aim of this study was to determine the role of inter-leukin (IL)-1 in response to XRT injury to the heart and on the cardiomyopathy development in the mouse. Female mice with genetic deletion of the IL-1 receptor type I (IL-1R1 knockout mice [IL-1R1 KO]) and treatment with recombinant human IL-1 receptor antagonist anakinra, 10 mg/kg twice daily for 7 d, were used as independent approaches to determine the role of IL-1. Wild-type (wt) or IL-1R1 KO mice were treated with a single session of XRT (20 or 14 gray [Gy]). Echocardiography (before and after isoproterenol challenge) and left ventricular (LV) catheterization were performed to evaluate changes in LV dimensions and function. Masson’s trichrome was used to assess myocardial fibrosis and pericardial thickening. After 20 Gy, the contractile reserve was impaired in wt mice at d 3, and the LV ejection fraction (EF) was reduced after 4 months when compared with sham-XRT. IL-1R1 KO mice had preserved contractile reserve at 3 d and 4 months and LVEF at 4 months after XRT. Anakinra treatment for 1 d before and 7 d after XRT prevented the impairment in contractile reserve. A significant increase in LV end-diastolic pressure, associated with increased myocardial interstitial fibrosis and pericardial thickening, was observed in wt mice, as well as in IL-1R1 KO-or anakinra-treated mice. In conclusion, induction of IL-1 by XRT mediates the development of some, such as the contractile impairment, but not all aspects of the XRT-induced cardiomyopathy, such as myocardial fibrosis or pericardial thickening.

Notes

Acknowledgments

The study was founded by a Virginia Commonwealth University Massey Cancer Pilot Research Study Award to A Abbate, by an explorative/development grant by the National Institute of Research to A Abbate and DA Gewirtz (ID 1R21CA171974-01A1), and by the American Heart Association with a Postdoctoral Fellowship grant to E Mezzaroma (ID 12POST11940005). DA Gewirtz was supported by an Institutional Research Grant (IRG-14-192-40) from the American Cancer Society. RB Mikkelsen was funded by National Institutes of Health grant 5U19AI10910361, University of Rochester Center for Medical Countermeasures against Radiation.

Supplementary material

10020_2015_2101210_MOESM1_ESM.pdf (416 kb)
Supplementary material, approximately 416 KB.

References

  1. 1.
    Lipshultz SE, et al. (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 128:1927–95.CrossRefGoogle Scholar
  2. 2.
    Jaworski C, Mariani JA, Wheeler G, Kaye DM. (2013) Cardiac complications of thoracic irradiation. J. Am. Coll. Cardiol. 61:2319–28.CrossRefGoogle Scholar
  3. 3.
    Lipshultz SE, Adams MJ. (2010) Cardiotoxicity after childhood cancer: beginning with the end in mind. J. Clin. Oncol. 28:1276–81.CrossRefGoogle Scholar
  4. 4.
    Mezzaroma E, et al. (2012) A mouse model of radiation-induced cardiomyopathy. Int. J. Cardiol. 156:231–3.CrossRefGoogle Scholar
  5. 5.
    Monceau V, et al. (2010) Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity. Curr. Drug Target. 11:1395–404.CrossRefGoogle Scholar
  6. 6.
    Seemann I, et al. (2012) Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother. Oncol. 103:143–50.CrossRefGoogle Scholar
  7. 7.
    Van Der Meeren A, Squiban C, Gourmelon P, Lafont H, Gaugler MH. (1999) Differential regulation by IL-4 and IL-10 of radiation-induced IL-6 and IL-8 production and ICAM-1 expression by human endothelial cells. Cytokine. 11:831–8.CrossRefGoogle Scholar
  8. 8.
    O’Brien-Ladner A, Nelson ME, Kimler BF, Wesselius LJ. (1993) Release of interleukin-1 by human alveolar macrophages after in vitro irradiation. Radiat. Res. 136:37–41.CrossRefGoogle Scholar
  9. 9.
    Tabata C, et al. (2006) All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system. Am. J. Physiol. Lung Cell Mol. Physiol. 290:L597–606.CrossRefGoogle Scholar
  10. 10.
    Bentzen SM. (2006) Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat. Rev. Cancer. 6:702–13.CrossRefGoogle Scholar
  11. 11.
    Dinarello CA. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720–32.CrossRefGoogle Scholar
  12. 12.
    Toldo S, et al. (2015) The inflammasome in myocardial injury and cardiac remodeling. Antioxid. Redox. Signal. 22:1146–61.CrossRefGoogle Scholar
  13. 13.
    Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. (2013) Targeting interleukin-1 in heart disease. Circulation. 128:1910–23.CrossRefGoogle Scholar
  14. 14.
    Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int. J. Radiat. Oncol. Biol. Phys. 33:99–109.CrossRefGoogle Scholar
  15. 15.
    Kruse JJ, et al. (2001) Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother. Oncol. 58:303–11.CrossRefGoogle Scholar
  16. 16.
    Van Tassell BW, et al. (2012) Enhanced inter-leukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 7:e33438.CrossRefGoogle Scholar
  17. 17.
    Toldo S, et al. (2014) Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am. J. Physiol. Heart Circ. Physiol. 306:H1205–31.CrossRefGoogle Scholar
  18. 18.
    Abbate A, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117:2670–83.CrossRefGoogle Scholar
  19. 19.
    Zhu J, et al. (2010) Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur. J. Pharmacol. 643:247–53.CrossRefGoogle Scholar
  20. 20.
    Abbate A, et al. (2011) Alterations in the inter-leukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One. 6:e27923.CrossRefGoogle Scholar
  21. 21.
    Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press.Google Scholar
  22. 22.
    Schiller NB, et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 2:358–67.CrossRefGoogle Scholar
  23. 23.
    Mezzaroma E, et al. (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl. Acad. Sci. U. S. A. 108:19725–30.CrossRefGoogle Scholar
  24. 24.
    Kong P, Christia P, Frangogiannis NG. (2014) The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71:549–74.CrossRefGoogle Scholar
  25. 25.
    Fajardo LF, Stewart JR, Cohn KE. (1968) Morphology of radiation-induced heart disease. Arch. Pathol. 86:512–9.PubMedGoogle Scholar
  26. 26.
    Chello M, et al. (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc. Surg. 4:222–6.CrossRefGoogle Scholar
  27. 27.
    Fu Y, et al. (2013) Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int. J. Mol. Sci. 14:14105–18.CrossRefGoogle Scholar
  28. 28.
    Stoecklein VM, et al. (2014) Radiation exposure induces inflammasome pathway activation in immune cells. J. Immunol. 194:1178–89.CrossRefGoogle Scholar
  29. 29.
    Robbins ME, Zhao W. (2004) Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int. J. Radiat. Biol. 80:251–9.CrossRefGoogle Scholar
  30. 30.
    Schaue D, Kachikwu EL, McBride WH. (2012) Cytokines in radiobiological responses: a review. Radiat. Res. 178:505–23.CrossRefGoogle Scholar
  31. 31.
    Fernandes-Alnemri T, et al. (2007) The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14:1590–604.CrossRefGoogle Scholar
  32. 32.
    Liu SJ, Zhou W, Kennedy RH. (1999) Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am. J. Physiol. 276:H141–8.PubMedGoogle Scholar
  33. 33.
    Van Tassell BW, et al. (2013) Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm Res. 62:637–40.CrossRefGoogle Scholar
  34. 34.
    Schultz-Hector S, Trott KR. (2007) Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int. J. Radiat. Oncol. Biol. Phys. 67:10–8.CrossRefGoogle Scholar
  35. 35.
    Vecile E, et al. (2013) Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes. PLoS One. 8:e53265.CrossRefGoogle Scholar
  36. 36.
    Lawrie A, et al. (2011) Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am. J. Pathol. 179:1693–705.CrossRefGoogle Scholar
  37. 37.
    Salloum FN, et al. (2009) Anakinra in experimental acute myocardial infarction: does dosage or duration of treatment matter? Cardiovasc. Drugs Ther. 23:129–35.CrossRefGoogle Scholar
  38. 38.
    Abbate A, Dinarello CA. (2015) Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? Eur. Heart J. 36:337–9.CrossRefGoogle Scholar
  39. 39.
    Bujak M, et al. (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173:57–67.CrossRefGoogle Scholar
  40. 40.
    Abbate A, et al. (2010) Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 12:319–22.CrossRefGoogle Scholar
  41. 41.
    Van Tassell BW, et al. (2010) Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J. Cardiovasc. Pharmacol. 55:117–22.CrossRefGoogle Scholar
  42. 42.
    Toldo S, et al. (2013) Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp. Physiol. 98:734–45.CrossRefGoogle Scholar
  43. 43.
    Gao XM, Dart AM, Dewar E, Jennings G, Du XJ. (2000) Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc. Res. 45:330–8.CrossRefGoogle Scholar
  44. 44.
    Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. (1977) The wavefront phenomenon of ischemic cell death, 1: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 56:786–94.CrossRefGoogle Scholar
  45. 45.
    Mookadam F, Jiamsripong P, Raslan SF, Panse PM, Tajik AJ. (2011) Constrictive pericarditis and restrictive cardiomyopathy in the modern era. Future Cardiol. 7:471–83.CrossRefGoogle Scholar
  46. 46.
    Puren AJ, Fantuzzi G, Dinarello CA. (1999) Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. U. S. A. 96:2256–61.CrossRefGoogle Scholar
  47. 47.
    Woldbaek PR, et al. (2003) Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. 59:122–31.CrossRefGoogle Scholar
  48. 48.
    Lee JK, et al. (2004) Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. U. S. A. 101:8815–20.CrossRefGoogle Scholar
  49. 49.
    Stuyt RJ, et al. (2005) Interleukin-18 does not modulate the acute-phase response. J. Endotoxin. Res. 11:85–8.CrossRefGoogle Scholar
  50. 50.
    Platis A, et al. (2008) The effect of daily administration of IL-18 on cardiac structure and function. Perfusion. 23:237–42.CrossRefGoogle Scholar
  51. 51.
    Yu Q, et al. (2009) IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 297:H76–85.CrossRefGoogle Scholar
  52. 52.
    Neriishi K, Nakashima E, Delongchamp RR. (2001) Persistent subclinical inflammation among A-bomb survivors. Int. J. Radiat. Biol. 77:475–82.CrossRefGoogle Scholar
  53. 53.
    Hayashi T, et al. (2003) Radiation dose-dependent increases in inflammatory response markers in A-bomb survivors. Int. J. Radiat. Biol. 79:129–36.CrossRefGoogle Scholar
  54. 54.
    Lipshultz SE, et al. (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J. Clin. Oncol. 30:1050–7.CrossRefGoogle Scholar
  55. 55.
    Van Tassell BW, et al. (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am. J. Cardiol. 113:321–7.CrossRefGoogle Scholar
  56. 56.
    Groarke JD, et al. (2015) Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J. Am. Coll. Cardiol. 65:573–83.CrossRefGoogle Scholar
  57. 57.
    Bower JE, et al. (2009) Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 15:5534–40.CrossRefGoogle Scholar
  58. 58.
    Lust JA, et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-in-duced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84:114–22.CrossRefGoogle Scholar
  59. 59.
    Anakinra or Denosumab and Everolimus in Advanced Cancer [Internet]. [study last updated 2015 Apr 7; cited 2015 Jun 11]. Available from: https://doi.org/www.clinicaltrials.gov/ct2/show/NCT01624766?term=NCT01624766&rank=1. ClinicalTrials.gov Identifier: NCT01624766.
  60. 60.
    Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer (IRAFU) [Internet]. [study last updated 2015 Mar 25; cited 2015 Jun 11]. Available from: https://doi.org/www.clinicaltrials.gov/ct2/show/study/NCT02090101?term=NCT02090101&rank=1. ClinicalTrials.gov Identifier: NCT02090101.
  61. 61.
    Toldo S, et al. (2015) Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc. Res. 105:203–12.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Eleonora Mezzaroma
    • 1
    • 2
    • 3
  • Ross B. Mikkelsen
    • 4
  • Stefano Toldo
    • 1
    • 2
  • Adolfo G. Mauro
    • 1
    • 2
  • Khushboo Sharma
    • 5
  • Carlo Marchetti
    • 1
    • 2
  • Asim Alam
    • 4
  • Benjamin W. Van Tassell
    • 1
    • 2
    • 3
  • David A. Gewirtz
    • 5
  • Antonio Abbate
    • 1
    • 2
  1. 1.Virginia Commonwealth University (VCU) Pauley Heart CenterRichmondUSA
  2. 2.VCU Victoria Johnson CenterRichmondUSA
  3. 3.School of Pharmacy, VCURichmondUSA
  4. 4.Radiation OncologyMassey Cancer Center, VCURichmondUSA
  5. 5.Pharmacology and ToxicologyMassey Cancer Center, VCURichmondUSA

Personalised recommendations